Clinical Trial Update: ANG1005 in Patients With Recurrent High-Grade Glioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ANG1005 in patients with recurrent high-grade glioma, including glioblastoma and other gliomas; status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor Recurrent
• Glioblastoma
• Glioma

Drugs mentioned

• ANG1005 (GRN1005)

Snippet

Sponsor: Angiochem Inc | Conditions: Glioma, Glioblastoma | Phase 2 | Status: COMPLETED